Literature DB >> 2126201

The carbonic anhydrase II gene, a gene regulated by thyroid hormone and erythropoietin, is repressed by the v-erbA oncogene in erythrocytic cells.

B Pain1, F Melet, P Jurdic, J Samarut.   

Abstract

The v-erbA oncogene encodes an altered form of the nuclear receptor of the thyroid hormone triiodothyronine (T3). This altered receptor is unable to bind T3, and blocks the differentiation of chicken erythrocyte progenitor cells. To identify the cellular target genes of v-ErbA in the transformed cells, we analysed the expression of several genes in normal erythrocytic cells exposed to T3, and found that the gene encoding carbonic anhydrase II is transcriptionally activated by the hormone. In contrast, this gene is repressed in erythroleukemic cells transformed by the v-erbA product. To investigate in more details the effects of v-ErbA, we constructed a mutant of v-ErbA in which we restored the ability to bind T3. This mutant developed its oncogenicity only in the absence of T3. Upon binding of T3, the transformed cells differentiated and immediately expressed the carbonic anhydrase II gene. These data show that v-ErbA directly inhibits the transcription of the carbonic anhydrase II gene, presumably by competing with normal T3 receptors. The carbonic anhydrase II gene is the first identified target gene of the v-ErbA oncoprotein in erythroleukemic cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126201

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  10 in total

1.  Multiple mutations contribute to repression by the v-Erb A oncoprotein.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

2.  Thyroid hormone receptor alpha1 directly controls transcription of the beta-catenin gene in intestinal epithelial cells.

Authors:  Michelina Plateroti; Elsa Kress; Jun Ichirou Mori; Jacques Samarut
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

3.  In vivo repression of an erythroid-specific gene by distinct corepressor complexes.

Authors:  Luc E G Rietveld; Eric Caldenhoven; Hendrik G Stunnenberg
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

4.  Myb-Ets fusion oncoprotein inhibits thyroid hormone receptor/c-ErbA and retinoic acid receptor functions: a novel mechanism of action for leukemogenic transformation by E26 avian retrovirus.

Authors:  A Rascle; N Ferrand; O Gandrillon; J Samarut
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

5.  v-jun cooperates with v-erbB to transform the thrombocytic/megakaryocytic lineage.

Authors:  M Garcia; J Samarut
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

6.  A hepatitis B virus pre-S-retinoic acid receptor beta chimera transforms erythrocytic progenitor cells in vitro.

Authors:  M Garcia; H de Thé; P Tiollais; J Samarut; A Dejean
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

7.  v-erbA acts on retinoic acid receptors in immature avian erythroid cells.

Authors:  S Sande; M Sharif; H Chen; M Privalsky
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

8.  Large-scale analysis by SAGE reveals new mechanisms of v-erbA oncogene action.

Authors:  Corinne Bresson; Celine Keime; Claudine Faure; Yann Letrillard; Maud Barbado; Sandra Sanfilippo; Najate Benhra; Olivier Gandrillon; Sandrine Gonin-Giraud
Journal:  BMC Genomics       Date:  2007-10-26       Impact factor: 3.969

9.  Transcriptional repression of band 3 and CAII in v-erbA transformed erythroblasts accounts for an important part of the leukaemic phenotype.

Authors:  S Fuerstenberg; I Leitner; C Schroeder; H Schwarz; B Vennström; H Beug
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

10.  Unliganded T3R, but not its oncogenic variant, v-erbA, suppresses RAR-dependent transactivation by titrating out RXR.

Authors:  D Barettino; T H Bugge; P Bartunek; M D Vivanco Ruiz; V Sonntag-Buck; H Beug; M Zenke; H G Stunnenberg
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.